
KFSH Conducts Nearly Half of Saudi Arabia's Registered Clinical Trials as Research Infrastructure Expands



NY, UNITED STATES, September 13, 2026 /EINPresswire.com/ -- King Faisal Specialist Hospital and Research Centre (KFSH) conducted 48% of all clinical trials registered in Saudi Arabia during the first half of 2025, supported by a specialist workforce able to move studies from scientific design through safe delivery to patients. Investigators, research nurses, pharmacists, coordinators, data specialists and regulatory and ethics teams form the operating capability behind the hospital's national share of clinical research.

Clinical trials provide the structured pathway through which new medicines, diagnostic approaches, medical devices and therapeutic procedures are evaluated in patients. They are essential to determining whether an innovation is safe, effective and capable of producing meaningful clinical benefit before it becomes part of wider medical practice.

KFSH established its centralized Clinical Trials service in 2020 to coordinate studies conducted by hospital clinicians and researchers. The service combines feasibility assessment, activation, trial operations and completion with the workforce needed to manage patient recruitment, investigational medicines, data quality, safety reporting, ethics and regulatory requirements. It also helps investigators work effectively with patients, sponsors and international research partners.

During the first half of 2025 the hospital recorded 104 active trials and 80 new studies underway. These extended across cancer, cardiovascular disease, autoimmune and musculoskeletal conditions, dermatology, gastroenterology, liver disease, and endocrine and metabolic disorders. This breadth allows patients with complex conditions to access emerging therapeutic options while generating evidence relevant to the Kingdom's healthcare needs.

One significant example involved the treatment of the first patient in a Phase I clinical trial using

genetically engineered CAR-T cells manufactured locally for relapsed acute lymphoblastic leukemia. The trial connected local scientific capability, advanced biomanufacturing and highly specialized clinical care within a single translational pathway.

KFSH's model also strengthens the Kingdom's ability to participate in complex international studies. Centralized trial management, research governance and specialist clinical infrastructure create a foundation for multinational collaboration while maintaining standards for ethics, patient safety, data quality and regulatory compliance.

Scientific ambition alone does not change patient care. Breakthroughs in AI, biotechnology, genomics and advanced therapeutics require strong clinical-trials systems capable of testing innovation responsibly and generating the evidence needed for adoption. KFSH will make this argument at the C3 US NYC Davos of Healthcare™ Summit 2026 in New York City on September 14.

King Faisal Specialist Hospital and Research Centre has been ranked first in the Middle East and Africa and 12th globally among the world's top 250 academic medical centers for 2026. It was also recognized as the most valuable healthcare brand in the Kingdom and the Middle East for 2026, according to Brand Finance, and listed by Newsweek among the World's Best Hospitals, World's Best Smart Hospitals, and World's Best Specialized Hospitals for 2026.

KFSH
Riyadh
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/940646763

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.